Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study.

Kanwar AJ, Vinay K, Sawatkar GU, Dogra S, Minz RW, Shear NH, Koga H, Ishii N, Hashimoto T.

Br J Dermatol. 2014 Jun;170(6):1341-9. doi: 10.1111/bjd.12972.

PMID:
24640990
2.

Low-dose rituximab is effective in pemphigus.

Horváth B, Huizinga J, Pas HH, Mulder AB, Jonkman MF.

Br J Dermatol. 2012 Feb;166(2):405-12. doi: 10.1111/j.1365-2133.2011.10663.x. Epub 2012 Jan 9.

PMID:
21967609
3.

Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity.

Daneshpazhooh M, Chams-Davatchi C, Khamesipour A, Mansoori P, Taheri A, Firooz A, Mortazavi H, Esmaili N, Dowlati Y.

J Eur Acad Dermatol Venereol. 2007 Nov;21(10):1319-24.

PMID:
17958835
4.

Commentary regarding clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study.

Yancey KB.

Dermatol Ther. 2015 May-Jun;28(3):174-5. doi: 10.1111/dth.12198. Epub 2015 Jan 30. No abstract available.

PMID:
25640417
5.

Evaluating efficacy of plasmapheresis for patients with pemphigus using desmoglein enzyme-linked immunosorbent assay.

Nagasaka T, Fujii Y, Ishida A, Handa M, Tanikawa A, Amagai M, Nishikawa T.

Br J Dermatol. 2008 Apr;158(4):685-90. doi: 10.1111/j.1365-2133.2007.08416.x. Epub 2008 Jan 30.

PMID:
18241273
6.
7.

Serum and salivary desmoglein 1 and 3 enzyme-linked immunosorbent assay in pemphigus vulgaris: correlation with phenotype and severity.

Hallaji Z, Mortazavi H, Lajevardi V, Tamizifar B, AmirZargar A, Daneshpazhooh M, Chams-Davatchi C.

J Eur Acad Dermatol Venereol. 2010 Mar;24(3):275-80. doi: 10.1111/j.1468-3083.2009.03408.x. Epub 2009 Aug 26.

PMID:
19709345
8.

Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy.

Feldman RJ, Christen WG, Ahmed AR.

Br J Dermatol. 2012 Mar;166(3):511-7. doi: 10.1111/j.1365-2133.2011.10658.x. Epub 2012 Jan 19.

PMID:
21967407
9.

A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone.

Hall RP 3rd, Fairley J, Woodley D, Werth VP, Hannah D, Streilein RD, McKillip J, Okawa J, Rose M, Keyes-Elstein LL, Pinckney A, Overington A, Wedgwood J, Ding L, Welch B.

Br J Dermatol. 2015 Mar;172(3):760-8. doi: 10.1111/bjd.13350. Epub 2015 Feb 5.

10.

[Prolonged complete clinical remission in patients with severe pemphigus vulgaris after cycles of intravenous cyclophosphamide].

España Alonso A, Panizo C, Fernández S, Marquina M, Pretel M, Aguado L, Sánchez-Ibarrola A.

Actas Dermosifiliogr. 2009 Mar;100(2):113-20. Spanish.

PMID:
19445875
11.

Comparison of desmoglein 1 and 3 enzyme-linked immunosorbent assay and direct immunofluorescence for evaluation of immunological remission in pemphigus vulgaris.

Daneshpazhooh M, Kamyab K, Kalantari MS, Balighi K, Naraghi ZS, Shamohammadi S, Mortazavizadeh SM, Ramezani A, Chams-Davatchi C.

Clin Exp Dermatol. 2014 Jan;39(1):41-7. doi: 10.1111/ced.12187. Epub 2013 Jun 19.

PMID:
23782219
12.

ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus.

Abasq C, Mouquet H, Gilbert D, Tron F, Grassi V, Musette P, Joly P.

Arch Dermatol. 2009 May;145(5):529-35. doi: 10.1001/archdermatol.2009.9.

PMID:
19451496
13.

Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3.

Cheng SW, Kobayashi M, Kinoshita-Kuroda K, Tanikawa A, Amagai M, Nishikawa T.

Br J Dermatol. 2002 Aug;147(2):261-5.

PMID:
12174096
14.

Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities.

Cho HH, Jin SP, Chung JH.

J Eur Acad Dermatol Venereol. 2014 Feb;28(2):186-91. doi: 10.1111/jdv.12080. Epub 2013 Jan 29.

PMID:
23356542
15.

Using desmoglein 1 and 3 enzyme-linked immunosorbent assay as an adjunct diagnostic tool for pemphigus.

Huang CH, Chen CC, Wang CJ, Chang YT, Liu HN.

J Chin Med Assoc. 2007 Feb;70(2):65-70.

16.

Rituximab exerts a dual effect in pemphigus vulgaris.

Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M.

J Invest Dermatol. 2008 Dec;128(12):2850-8. doi: 10.1038/jid.2008.172. Epub 2008 Jun 19.

17.

Efficacy and safety of rituximab treatment in Indian pemphigus patients.

Kanwar AJ, Tsuruta D, Vinay K, Koga H, Ishii N, Dainichi T, Hashimoto T.

J Eur Acad Dermatol Venereol. 2013 Jan;27(1):e17-23. doi: 10.1111/j.1468-3083.2011.04391.x. Epub 2011 Dec 17.

PMID:
22176540
18.

Evaluation of commercially available ELISA assays as a tool for monitoring and managing pemphigus patients: a prospective study.

Bracke S, Speeckaert R, Van Geel N, De Bacquer D, Lambert J.

Eur J Dermatol. 2013 Jan-Feb;23(1):33-9. doi: 10.1684/ejd.2012.1901.

PMID:
23302186
19.

Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).

Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R.

Dermatology. 2007;214(4):310-8.

PMID:
17460402
20.

Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption.

Eming R, Rech J, Barth S, Kalden JR, Schuler G, Harrer T, Hertl M.

Dermatology. 2006;212(2):177-87.

PMID:
16484825
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk